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ABSTRACT
Systems pharmacology is an emergent area that
studies drug action across multiple scales of com-
plexity, from molecular and cellular to tissue and
organism levels. There is a critical need to develop
network-based approaches to integrate the growing
body of chemical biology knowledge with network
biology. Here, we report ChemProt, a disease
chemical biology database, which is based on a
compilation of multiple chemical–protein annotation
resources, as well as disease-associated protein–
protein interactions (PPIs). We assembled more
than 700 000 unique chemicals with biological anno-
tation for 30 578 proteins. We gathered over
2-million chemical–protein interactions, which were
integrated in a quality scored human PPI network of
428 429 interactions. The PPI network layer allows
for studying disease and tissue specificity through
each protein complex. ChemProt can assist in the
in silico evaluation of environmental chemicals,
natural products and approved drugs, as well as
the selection of new compounds based on their
activity profile against most known biological
targets, including those related to adverse drug
events. Results from the disease chemical biology
database associate citalopram, an antidepressant,
with osteogenesis imperfect and leukemia and
bisphenol A, an endocrine disruptor, with certain
types of cancer, respectively. The server can
be accessed at http://www.cbs.dtu.dk/
services/ChemProt/.
INTRODUCTION
The old drug design paradigm, i.e. drugs interact selectively
with one or two targets (proteins), resulting in treatment
and prevention of disease, is now challenged by several
studies that show most drugs interacting with multiple
targets (‘polypharmacology’) (1,2). For example, celecoxib,
often considered a selective cyclooxygenase-2 non-steroidal
anti-inﬂammatory drug (NSAID), has been documented
to be active on at least two additional targets,
namely carbonic anhydrase II and 5-lipoxygenase (3).
Rosiglitazone, which has been used for the treatment of
type II diabetes mellitus, not only stimulates
the peroxisome proliferator activated receptor g, but also
blocks interferon gamma-induced chemokine expression in
Graves disease or ophthalmopathy (4). Polypharmacology
is not always beneﬁcial, as it often causes side effects:
Cisapride, which acts as a serotonergic 5-HT4 receptor
agonist, as well as astemizole, which blocks histamine H1
receptors (H1Rs), have both been withdrawn from all
markets due to the risk of fatal cardiac arrhythmia
associated with their blockade of the hERG potassium
ion channel, an unanticipated and undesirable ‘anti-target’
associated to QT prolongation and ‘torsades de pointes’
(5). However, ‘target’ and ‘anti-targets’ are dynamic
attributes, as exempliﬁed by the case of H1R antagonists
and their (in)ability to achieve clinically signiﬁcant levels in
the brain, inﬂuenced by the ATP-binding cassette trans-
porter ABCB1 (also known as P-glycoprotein), which
efﬂuxes some of these drugs from the brain (6). Acquiring
knowledge of the complete pharmacology proﬁle has
inspired new strategies to predict and to characterize
drug-target associations in order to improve the success
rates of current drug discovery paradigms, i.e. increase
the efﬁcacy and reduce toxicity and adverse effects (2).
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As large-scale chemical bioactivity databases are
being assembled, the polypharmacology (i.e. high afﬁnity
bioactivity across related targets) and promiscuity
(i.e. low afﬁnity across multiple families) of chemicals are
expanding the chemical space for druggable targets (7).
These studies are often focused on speciﬁc protein
families, such as G-protein coupled receptors (8), nuclear
receptors (9) and kinases (10), but global pharmacology
proﬁles of chemicals are considered as well (1,2). Recent
chemoinformatics advances support the development
of polypharmacology data mining, e.g. via iPHACE, an
integrative web-based tool that enables pharmacological
space navigation for small molecule drugs (11) or based
on a Similarity Ensemble Approach (SEA) to relate
protein pharmacology by ligand chemistry (12).
Biological information can also be retrieved for a large
set of chemical compounds through PubChem (13),
CheBI and ChEMBL (14).
Two conceptual developments support polypharma-
cology: systems pharmacology, aimed at drug actions
in the context of regulatory networks (15); and systems
chemical biology (16), which introduces chemical aware-
ness in systems biology. Since proteins rarely operate in
isolation inside and outside cells, but rather function in
highly interconnected cellular pathways, interactome
networks have been developed by data integration.
Yildirim et al. (17) combined FDA-approved drugs with
a human protein–protein interaction (PPI) network
(human interactome) in order to analyze the interrelation-
ships between drug targets and disease–gene products i.e.
disease–proteins. Similar work has been based on
PubChem bioassays as source of polypharmacology (18).
The use of side-effect similarity has been proposed on
the assumption that drugs with similar side-effects
are likely to interact with similar target proteins (19).
Recent advances include a protein–protein association
network based on the chemical toxicology of environ-
mental chemicals (20) and a human disease network
linking disorders and disease genes to various known
phenotypes (21).
Our goal in the present work was to develop a disease
chemical biology server, called ChemProt, based on the
integration of chemical–protein annotation resources that
are now accessible from large repositories, and curated
disease-linked PPI data (22). ChemProt is designed to
assist the elucidation of drug actions in the context of
cellular and disease networks. Further to that, it allows
the identiﬁcation of additional genes that may play major
roles in modulating chemical response i.e. to drugs, envir-
onmental chemicals and natural products, thus leading to
new options in drug discovery and environmental chemical
evaluation. Lastly, the ChemProt server could contribute
to drug repurposing as well as to the investigation of
chemicals related to anti-targets and adverse drug events.
IMPLEMENTATION
Data sources
We ﬁrst gathered chemical–protein interaction data
from different open source databases i.e. ChEMBL
(version chembl_05) (14), BindingDB (23), PDSP Ki
Database (24), DrugBank (version2.5) (25), PharmGKB
(26) and two commercial databases, WOMBAT (version
2009) and WOMBAT-PK (version 2008) (7). Active
compounds from the PubChem bioassay (2010) have
been collected as well (13). We considered only active
compounds from ‘conﬁrmatory’ assays in order to
capture high-conﬁdence chemical–protein annotations
from PubChem. These databases provide experimental
evidence of chemical–protein interactions. Drug-target in-
formation was collected from DrugBank and PharmGKB.
In addition, we integrated chemical–protein associations
from CTD (version 2009) (27) and STITCH (version
STITCH 2.0) (28). These last two databases consider the
effect or modulation (positive or negative) of a chemical
on proteins, other than that deﬁned as binding activity.
Examples include gene expression or pathway data, where
the deregulation of a gene by a chemical may be not due to
a physical interaction between the two entities but a
response at a cellular level. Duplicate chemicals from the
multiple databases were found by using InChI keys and
were merged into a single ChemProt ID. However, the
biological information associated to each chemical was
conserved for users looking on selective databases.
Overall, the ﬁnal database contains 700 000 distinct
molecules annotated for 30 578 proteins.
Descriptors and similarity measurement
The chemical structure of the molecules was encoded
using two rather different types of ﬁngerprints. The
166 MACCS keys, encode the presence or absence of
predeﬁned substructural or functional groups (29). On
the other hand, a more complex 3-point pharmacophore
ﬁngerprint (GpiDAPH3) is based on an expansion of the
PATTY pharmacophore feature recognition scheme of a
2D structure (30). This scheme assigns one or more
pharmacophore feature types to all atoms in a molecule
using a predeﬁned list of SMART queries. The list of
pharmacophore feature types comprises: hydrogen-bond
donor (D), hydrogen-bond acceptor (A), polar (P) and
hydrophobic (H). In addition, an extra label (p or pi) is
added to each feature if the originating atom or group is
sp2-hybridized or planar for other reasons. The
GpiDAPH3 pharmacophore feature scheme is expressed
in 2D as triplet feature combinations with a graph based
inter-atom distance binning scheme. Both ﬁngerprints are
implemented in the Molecular Operating Environment
(MOE, version 2008.10) (31). The similarity between two
molecules is measured using the Tanimoto coefﬁcient (Tc),
a method of choice for the computation of ﬁngerprint-
based similarity (32). The Tc is deﬁned as the number of
bits in common divided by the total number of used bits in
both molecules. For any pair of chemicals, Tc assumes
values between 0 and 1. A high Tc represents high
similarity.
PPI network
The human interactome used is an in-house protein–
protein interaction network inferred from experiments in
both humans and model organisms (22). Using an
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elaborate scoring scheme, all interactions have been
validated against a gold standard (33). The current
interactome contains 428 429 unique protein–proteins
interactions derived from source databases such as
BIND (34), GRID (35), MINT (36), dip_full (37),
HPRD (38), intact (39), mppi (40), MPact (41),
Reactome (42) and KEGG (43). Data are transferred
between organisms by using the Inparanoid orthology
database (44). In total the human interactome comprises
22 997 genes.
Human disease genes and complexes
Based on a previous study (45), disease-associated protein
complexes were associated to the chemical–protein anno-
tation by mining OMIM (46) and GeneCards (47), two
data resources for genes association to diseases, we col-
lected a list of 2227 unique disease-related proteins and
mapped the complexes of genes to disease. Similarly,
complexes of genes were mapped to Gene Ontology
(GO) terms (48) and tissues by using the expression data
from 73 non-disease tissues from the Novartis Research
Foundation Gene Expression Database (GNF) (49) and
Human Protein Atlas (50). Users of ChemProt can thus
retrieve gene complexes that are related to a query
chemical and visualize the annotations of each complex.
APPLICATIONS
Chemical–protein interactions
Chemicals can be searched using a common name,
SMILES and by drawing the 2D structure, or retrieved
through their annotation to a protein. Users can then
choose the descriptor space and the Tc threshold to be
used for similarity search. Following a successful query,
hits grouped by species will be returned, together with
computed physico-chemical properties such as Molecular
Weight, LogP, the number of hydrogen bond donors and
acceptors, the number of rigid bonds and the number of
rings, based on the Marvin applet from Chemaxon (51).
Hits are provided separately for known annotations, and
for prediction of small molecule bioactivity, respectively.
The biochemical and pharmacological effects of a
chemical, e.g. substrate, inhibitor, agonist or antagonist,
are provided if such information is available, together with
hyperlinks to UniProt and Ensembl, which lead to more
information on protein sequence and function,
respectively.
From chemical–protein interactions to complex protein–
disease associations
The unique feature of ChemProt is that it offers the user
the possibility to get information at a cellular level, by
linking chemically-induced biological perturbations to
speciﬁc tissues and phenotypes.
Proteins that are both affected by a chemical and par-
ticipate in one or more protein complexes are highlighted
in the results table of the ChemProt server. By clicking on
the protein, the user is redirected to the ‘Disease
complexes’ server and has to choose which complex to
visualize. On the ‘Disease complexes’ server, size and il-
lustrations of the protein network are provided.
Additionally, enrichment analysis results of the proteins
in the complex are shown, with respect to disease associ-
ation (OMIM, BioAlma), GO terms (biological process,
cellular component) and tissue speciﬁcity (Human Protein
Atlas, GNF). To ensure that the complexes were biologic-
ally relevant entities, the enrichment of the biological
terms (OMIM, GO,. . .) was compared to randomly
generated complexes (1.0e6). The signiﬁcances were
calculated using a hyper-geometric test and the P-value
for the most signiﬁcant enriched term for each of the
data types was calculated as previously described (45).
The table presenting the OMIM enrichment results is
interactively linked with an illustration of the protein
complex where proteins associated with the selected
disease are colored yellow.
Output of the chemical–proteins interactions and
disease complexes can be downloaded from the
ChemProt website. In addition, the ‘Reﬂect’ service
provides further information on chemicals and genes
(52). ‘Reﬂect’ tags gene, protein and small molecule
names in text and offers the opportunity to quickly view
additional information on the ChemProt results, including
synonyms, protein sequences, domains, 3D structures and
subcellular location.
EXAMPLES
With the integration of several databases, ChemProt not
only provides pharmacological information, but also
includes biological data associated to environmental
chemicals and natural products. As seen in the examples
below, ChemProt can be queried for drugs as well as
environmental chemicals. A search for citalopram, an
antidepressant, illustrates the complementarity of the
integrated databases within ChemProt (Figure 1).
Marketed as a selective serotonin reuptake inhibitor
(SSRI) (DrugBank), this drug displays bioactivity on
seven human proteins (ChEMBL). Via ChemProt, four
other proteins (DRD3, 5HT1B, 5HT3, ADRA2A) are
retrieved from the Ki database. Additional information
on drug-target associations is provided by STITCH and
CTD. From the ﬁrst annotation to the D4 dopamine
receptor (DRD4), the disease term (under Disease
Complexes) is highlighted, indicating that protein–
protein interaction information for this protein is avail-
able. Using the link to the Disease Complexes server,
one ﬁnds that DRD4 interacts with three proteins (SRC,
GRB2 and NCK1). According to OMIM, this protein
network is associated to osteogenesis imperfecta and
leukemia and, according to BioAlma, to several psychotic
disorders. GO enrichment indicates signiﬁcant association
of the protein complex to signal complex formation and
vesicle membrane. Furthermore, tissue annotation
suggests that this complex is mainly expressed in follicle
and non-follicle cells (HPA) and dentritic cells (GNF).
Although it might be surprising to see a connection
between antidepressant and leukemia, it has been shown
recently that antidepressants such as chlomipramine and
Nucleic Acids Research, 2011, Vol. 39, Database issue D369
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ﬂuoxetine reduce the growth of B-cell malignancies in
leukemia (53).
The second query, ‘bisphenol A’ (BPA), is an environ-
mental pollutant used as plasticizer (54). BPA has bio-
logical activity on the estrogen receptor a (ESR1), the
androgen receptor (AR) and the estrogen related
receptor gamma (ERR3). However, several other
proteins are retrieved from CTD and STITCH based on
association data with this chemical. Looking at ESR1 in
the Disease Complexes server, a complex of 17 proteins is
depicted (complex 265) with signiﬁcant associations to
Li-FRAUMENI syndrome, breast cancer and neoplasms.
Enrichment analysis indicates that the complex is found in
the nucleus (GO cellular component), involved in the
regulation of metabolic processes and transcriptionally
regulated by the RNA polymerase II promoter (GO bio-
logical process). Furthermore, data from immunohisto-
chemistry studies suggest that the complex is mainly
located in the endometrium and the cerebral cortex
(HPA). The disease chemical biology network for BPA
indicates that, under certain conditions, this chemical
may be associated with certain types of cancers.
We have illustrated that ChemProt integrates molecu-
lar, cellular and phenotypic data associated to small mol-
ecules, which can lead to novel links and suggest new
avenues for research. We envisage that the ChemProt
server will ﬁnd applications within a variety of
chemogenomics, polypharmacology and systems
chemical biology studies. ChemProt will be updated
once a year with new compounds, new interactions and
more sophisticated descriptors.
ACKNOWLEDGEMENTS
Sunset Molecular Discovery LLC (www.sunsetmolecular
.com) contributed with the WOMBAT databases.
FUNDING
EU (DEER); Innovative Medicines Initiative Joint
Undertaking (eTOX); Danish Research Council for
Technology and Production Sciences; Lundbeck
Figure 1. Chemical–protein annotation and disease associations retrieved from ChemProt for the compound citalopram. (1) The compound can be
queried using different formats (name, SMILES and structure). (2) A query results in a table showing protein annotations and bioactivity predictions
for the compound. (3) Finally, a protein–protein interaction network (protein–complex) for a target protein can be depicted and disease associations
(OMIM and BioAlma) and other biological components (GO terms, HPA and mRNA expression) are displayed.
D370 Nucleic Acids Research, 2011, Vol. 39, Database issue
 at The Technical K
now
ledge Center of D
enm
ark on O
ctober 1, 2012
http://nar.oxfordjournals.org/
D
ow
nloaded from
 
foundation and the Villum Rasmussen Foundation.
Funding for open access charge: DEER.
Conﬂict of interest statement. None declared.
REFERENCES
1. Paolini,G.V., Shapland,R.H., van Hoorn,W.P., Mason,J.S. and
Hopkins,A.L. (2006) Global mapping of pharmacological space.
Nat. Biothechnol., 24, 805–815.
2. Keiser,M.J., Setola,V., Irwin,J.J., Laggner,C., Abbas,A.I.,
Hufeisen,S.J., Jensen,N.H., Kuijer,M.B., Matos,R.C., Tran,T.B.
et al. (2009) Predicting new molecular targets for known drugs.
Nature, 462, 175–181.
3. Mestres,J., Gregori-Puigjane´,E., Valverde,S. and Sole´,R.V. (2009)
The topology of drug-target interaction networks: implicit
dependence on drug properties and target families. Mol. Biosyst.,
5, 1051–1057.
4. Antonelli,A., Ferrari,S.M., Fallahi,P., Piaggi,S., Paolicchi,A.,
Franceschini,S.S., Salvi,M. and Ferrannini,E. (2010) Cytokines
(interferon-gamma and tumor necrosis factor-alpha)-induced
nuclear factor-kappaB activation and chemokine (C-X-C motif)
ligand 10 release in Graves disease and ophthalmopathy are
modulated by pioglitazone. Metabolism, doi:10.1016/j.metabol
.2010.02.002.
5. Vaz,R.J. and Klabunde,T. (2008) Antitargets: Prediction and
prevention of drug side effects. In Mannhold,R., Kubinyi,H. and
Folkers,G. (eds), Methods and Principles in Medicinal Chemistry.
Wiley-VCH, Weinheim.
6. Broccatelli,F., Carosati,E., Cruciani,G. and Oprea,T.I. (2010)
Transporter-mediated efﬂux inﬂuences CNS side effects: ABCB1,
from antitarget to target. Mol. Inf., 29, 16–26.
7. Olah,M., Rad,R., Ostopovici,L., Bora,A., Hadaruga,N.,
Hadaruga,D., Moldovan,R., Fulias,A., Mracec,M. and Oprea,T.I.
(2007) WOMBAT and WOMBAT-PK: bioactive databases for
lead and drug discovery. In Schreiber,S.L., Kapoor,T.M. and
Wess,G. (eds), Chemical Biology: From Small Molecules to
Systems Biology and Drug Design. Wiley-VCH, New York,
pp. 760–786.
8. Weill,N. and Rognan,D. (2009) Development and validation of a
novel protein-ligand ﬁngerprint to mine chemogenomic space:
application to G-protein coupled receptors and their ligands.
J. Chem. Inf. Model., 49, 1049–1062.
9. Mestres,J., Martin-Couce,L., Grgori-Puigjane´,E., Cases,M. and
Boyer,S. (2006) Ligand-based approach to in silico pharmacology:
nuclear receptor proﬁling. J. Chem. Inf. Model., 46, 2725–2736.
10. Knight,Z.A., Lin,H. and Shokat,K.M. (2010) Targeting the cancer
kinome through polypharmacology. Nat. Rev. Cancer, 10,
130–137.
11. Garcia-Serna,R., Ursu,O., Oprea,T.I. and Mestres,J. (2010)
iPHACE: integrative navigation in pharmacological space.
Bioinformatics, 26, 985–986.
12. Keiser,M.J., Roth,B.L., Armbruster,B.N., Ernsberger,P., Irwin,J.J.
and Shoichet,B.K. (2007) Relating protein pharmacology by
ligand chemistry. Nat. Biotechnol., 25, 197–206.
13. Wheeler,D.L., Barrett,T., Benson,D.A., Bryant,S.H., Canese,K.,
Chetvernin,V., Church,D.M., DiCuccion,M., Edgar,R.,
Federhen,S. et al. (2007) Databases resources of the National
Center for Biotechnology Information. Nucleic Acids Res., 35,
D5–D12.
14. de Matos,P., Alca´ntara,R., Dekker,A., Ennis,M., Hastings,J.,
Haug,K., Spiteri,I., Turner,S. and Steinbeck,C. (2010) Chemical
entities of biological interest: an update. Nucleic Acids Res., 38,
D249–D254.
15. Berger,S.I. and Iyengar,R. (2009) Network analyses in systems
pharmacology. Bioinformatics, 25, 2466–2472.
16. Oprea,T.I., Tropsha,A., Faulon,J.L. and Rintoul,M.D. (2007)
Systems chemical biology. Nat. Chem. Biol., 3, 447–450.
17. Yildirim,M.A., Goh,K.I., Cusick,M.E., Baraba´si,A.L. and
Vidal,M. (2007) Drug-target network. Nat. Biotechnol., 25,
1119–1126.
18. Chen,B., Wild,D. and Guha,R. (2009) PubChem as a source of
polypharmacology. J. Chem. Inf. Model., 49, 2044–2055.
19. Kuhn,M., Campillos,M., Letunic,I., Jensen,L.J. and Bork,P.
(2010) A side effect resource to capture phenotypic effects of
drugs. Mol. Syst. Biol., 6, 343.
20. Audouze,K., Juncker,A.S., Roque,F.J., Krysiak-Baltyn,K.,
Weinhold,N., Taboureau,O., Jensen,T.S. and Brunak,S. (2010)
Deciphering diseases and biological targets for environmental
chemicals using toxicogenomics networks. PLoS Comput. Biol., 6,
e10000788.
21. Goh,K.I., Cusick,M.E., Valle,D., Childs,B., Vidal,M. and
Baraba´si,A.L. (2007) The human disease network. Proc. Natl
Acad. Sci. USA, 104, 8685–8690.
22. Lage,K., Karlberg,E.O., Størling,Z.M., Olason,O.I.,
Pedersen,A.G., Rigina,O., Hinsby,A.M., Tu¨mer,Z., Pociot,F.,
Tommerup,N. et al. (2007) A human phenome-interactome
network of protein complexes implicated in genetic disorders.
Nat. Biotechnol., 25, 309–316.
23. Liu,T., Lin,Y., Wen,X., Jorissen,R.N. and Gilson,M.K. (2007)
Binding DB: a web-accessible database of experimentally
determined protein-ligand binding afﬁnities. Nucleic Acids Res.,
35, D198–D201.
24. Roth,B., Lopez,E., Beischel,S., Weskaemper,R.B. and Evans,J.M.
(2004) Screening the receptorome to discover the molecular
targets for plant-derived psychoactive compounds: a novel
approach for CNS drug discovery. Pharmacol. Ther., 102, 99–110.
25. Wishart,D.S., Knox,C., Guo,A.C., Shrivastava,S., Hassanali,M.,
Stothard,P., Chang,Z. and Woolsey,J. (2006) DrugBank: a
comprehensive resource for in silico drug discovery and
exploration. Nucleic Acids Res., 34, D668–D672.
26. Hewett,M., Oliver,D.E., Rubin,D.L., Easton,K.L., Stuart,J.M.,
Altman,R.B. and Klein,T.E. (2002) PharmGKB: the
pharmacogenetics knowledge base. Nucleic Acids Res., 30,
163–165.
27. Davis,A.P., Murphy,C.G., Saraceni-Richards,C.A.,
Rosentrein,M.C., Wiegers,T.C. and Mattingly,C.J. (2009)
Comparative toxicogenomics database: a knowledgebase and
discovery tool for chemical-gene-disease networks. Nucleic Acids
Res., 37, D786–D792.
28. Kuhn,M., Szklarczyk,D., Franceschini,A., Campillos,M., von
Mering,C., Jensen,L.J., Beyer,A. and Bork,P. (2010) STITCH 2:
an interaction network database for small molecules and proteins.
Nucleic Acids Res., 38, D552–D556.
29. Durant,J.L., Leland,B.A., Henry,D.R. and Nourse,J.G. (2002)
Reoptimization of MDL keys for use in drug discovery.
J. Chem. Inf. Comput. Sci., 42, 1273–1280.
30. Bush,B.L. and Sheridan,R.P. (1993) Patty: a programmable atom
typer and language for automatic classiﬁcation of atoms in
molecular databases. J. Chem. Inf. Comput. Sci., 33, 756–762.
31. MOE (version 2007.09), Chemical Computing Group, Montreal,
Canada. www.chemcomp.com (29 September 2010, date last
accessed).
32. Willet,P. (2006) Similarity-based virtual screening using 2D
ﬁngerprints. Drug Discov. Today, 11, 1046–1053.
33. Rual,J.F., Venkatesan,K., Hao,T., Dricot,A., Hirozane-
Kishikawa,T., Li,N., Berriz,G.F., Gibbons,F.D., Dreze,M.,
Ayivi-Guedehoussou,N. et al. (2005) Towards a proteome-scale
map of the human protein-protein interaction network. Nature,
437, 1173–1178.
34. Bader,G.D., Betel,D. and Hogue,C.W. (2003) BIND: the
biomolecular interaction network database. Nucleic Acids Res.,
31, 248–250.
35. Stark,C., Breitkreutz,B.J., Reguly,T., Boucher,L., Breitkreutz,A.
and Tyers,M. (2006) BioGRID: a general repository for
interaction datasets. Nucleic Acids Res., 34, D535–D539.
36. Zanzoni,A., Montecchi-Palazzi,L., Quondam,M., Ausiello,G.,
Helmer-Citterich,M. and Cesareni,G. (2002) MINT: a molecular
interaction database. FEBS Lett., 513, 135–140.
37. Salwinski,L., Miller,C., Smith,A., Pettit,F., Bowie,J. and
Eisenberg,D. (2004) The database of interacting proteins: 2004
update. Nucleic Acids Res., 32, D449–D451.
38. Mishra,G., Suresh,M., Kumaran,K., Kannabiran,N., Suresh,S.,
Bala,P., Shivakumar,K., Anuradha,N., Reddy,R., Raghavan,T.M.
Nucleic Acids Research, 2011, Vol. 39, Database issue D371
 at The Technical K
now
ledge Center of D
enm
ark on O
ctober 1, 2012
http://nar.oxfordjournals.org/
D
ow
nloaded from
 
et al. (2006) Human protein reference database – 2006 update.
Nucleic Acids Res., 34, D411–D414.
39. Hermjakob,H., Montecchi-Palazzi,L., Lewington,C., Mudali,S.,
Kerrien,S., Orchard,S., Vingron,M., Roechert,B., Roepstorff,P.,
Valencia,A. et al. (2004) IntAct: an open source molecular
interaction database. Nucleic Acids Res., 32, D452–D455.
40. Pagel,P., Kovac,S., Oesterheld,M., Braumer,B., Dunger-
Kaltenbach,I., Frishman,G., Montrone,C., Mark,P., Stumpﬂen,V.,
Mewes,H.W. et al. (2005) The MIPS mammalian protein-protein
interaction database. Bioinformatics, 21, 832–834.
41. Guldener,U., Munsterkotter,M., Oesterheld,M., Pagel,P.,
Ruepp,A., Mewes,H.W. and Stumpﬂen,V. (2006) MPact: the
MIPS protein interaction resource on yeast. Nucleic Acids Res.,
34, D436–D441.
42. Joshi-Tope,G., Gillespie,M., Vastrik,I., D’Eustachio,P.,
Schmidt,E., de Bono,B., Jassal,B., Gopinath,G.R., Wu,G.R.,
Matthews,L. et al. (2005) Reactome: a knowledgebase of
biological pathways. Nucleic Acids Res., 33, D428–D432.
43. Kanehisa,M., Goto,S., Hattori,M., Aoki-Kinoshita,K.F., Itoh,M.,
Kawashima,S., Katayama,T., Araki,M. and Hirakawa,M. (2006)
From genomics to chemical genomics: new developments in
KEGG. Nucleic Acids Res., 34, D354–D357.
44. O’Brien,K.P., Remm,M. and Sonnhammer,E.L. (2005)
Inparanoid: a comprehensive database of eukaryotic orthologs.
Nucleic Acids Res., 33, D476–D480.
45. Lage,K., Hansen,N.T., Karlberg,E.O., Eklund,A.C., Roque,F.S.,
Donahoe,P.K., Szallasi,Z., Jensen,T.S. and Brunak,S. (2008) A
large-scale analysis of tissue-speciﬁc pathology and gene
expression of human disease genes and complexes. Proc. Natl
Acad. Sci. USA, 105, 20870–20875.
46. Hamosh,A., Scott,A.F., Amberger,J.S., Bocchini,C.A. and
McKusick,V.A. (2005) Online Mendelian Inheritance in Man
(OMIM), a knowledgebase of human genes and genetic disorders.
Nucleic Acids Res., 33, D514–D517.
47. Safran,M., Solomon,I., Shmueli,O., Lapidot,M., Shen-Orr,S.,
Adat,A., Ben-Dor,U., Esterman,N., Rosen,N., Peter,I. et al.
(2002) GeneCards 2002: towards a complete, object-oriented,
human gene compendium. Bioinformatics, 18, 1542–1543.
48. Camon,E., Magrane,M., Barrell,D., Lee,V., Dimmer,E., Maslen,J.,
Binns,D., Harte,N., Lopez,R. and Apweiler,R. (2004) The
gene ontology annotation (GOA) database – sharing knowledge
in Uniprot with gene ontology. Nucleic Acids Res., 32,
D262–D266.
49. Su,A.I., Wiltshire,T., Batalov,S., Lapp,H., Ching,K.A., Block,D.,
Zhang,J., Soden,R., Hayakawa,M., Kreiman,G. et al. (2004) A
gene atlas of the mouse and human protein-encoding
transcriptomes. Proc. Natl Acad. Sci. USA, 101, 6062–6067.
50. Ponten,F., Jirstro¨m,K. and Uhlen,M. (2008) The human protein
atlas – a tool for pathology. J. Pathol., 216, 387–393.
51. Marvin, version5.3. http://www.chemaxon.com/ (29 September
2010, date last accessed).
52. Paﬁlis,E., O’Donoghue,S.I., Jensen,L.J., Horn,H., Kuhn,M.,
Brown,N.P. and Schneider,R. (2009) Reﬂect: augmented browsing
for the life scientist. Nat. Biotechnol., 27, 508–510.
53. Chamba,A., Holder,M.J., Jarrett,R.F., Shield,L., Toellner,K.M.,
Drayson,M.T., Barnes,N.M. and Gordon,J. (2010) SLC6A4
expression and anti-proliferative responses to serotonin
transporter ligands ﬂuoxetine in primary B-cell malignancies.
Leuk. Res., 34, 1103–1106.
54. Halden,R.U. (2010) Plastics and health risks. Annu. Rev. Public
Health., 31, 179–194.
D372 Nucleic Acids Research, 2011, Vol. 39, Database issue
 at The Technical K
now
ledge Center of D
enm
ark on O
ctober 1, 2012
http://nar.oxfordjournals.org/
D
ow
nloaded from
 
